Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065077 · ClinicalTrials.gov registry record · Phase 2
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A Phase 2 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01065077 is a Phase 2 study that was terminated before completion, run by Bayer. The registered enrollment target is 12 participants.
The verdict
NCT01065077, a Phase 2 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
Interventions
- DRUG Placebo
- DRUG Cinaciguat (BAY58-2667)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01065077
The ClinicalTrials.gov registry entry for NCT01065077 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01065077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01065077 about?
NCT01065077 is a clinical study titled "BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)". A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute decompensated heart failure.
What is the current status of trial NCT01065077?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2010-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01065077?
The interventions under investigation include: Placebo (DRUG), Cinaciguat (BAY58-2667) (DRUG).
Who is sponsoring clinical trial NCT01065077?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.